Transatlantic Tremors: How US Drug Pricing Reforms Are Reshaping the Global Pharmaceutical Landscape
Historic Shift: White House Reviews Landmark Drug Price Negotiation Rule
Market Movers: Unpacking the Week's Most Impactful Corporate Deals and Strategic Shifts
Roche's Strategic Investment Ignites Excitement in the MASH Drug Development Landscape
The Next Battleground: Novo Nordisk and Eli Lilly's Hundred-Year War for Oral GLP-1 Dominance
Metsera: The New Power Player Set to Disrupt the $100 Billion GLP-1 Market
Mpox in Africa: A Grave, Enduring Health Emergency Declared by WHO
Halozyme gains as U.S. and EU clear Enhanze based products